214450 — PharmaResearch Co Balance Sheet
0.000.00%
Last trade - 00:00
- KR₩1tn
- KR₩1tn
- KR₩261bn
- 91
- 26
- 62
- 67
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | — | — | — | — | — |
Source: | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts |
Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
Status: | Final | Final | Final | Final | Final |
Cash | |||||
Cash and Equivalents | |||||
Short Term Investments | |||||
Cash and Short Term Investments | 69,029 | 79,267 | 156,798 | 184,343 | 160,298 |
Net Total Accounts Receivable | |||||
Net Total Receivables | 20,589 | 26,351 | 30,510 | 36,415 | 36,330 |
Total Inventory | |||||
Prepaid Expenses | |||||
Total Other Current Assets | |||||
Total Current Assets | 104,473 | 127,404 | 206,792 | 247,345 | 256,465 |
Gross Property, Plant And Equipment | |||||
Accumulated Depreciation | |||||
Net Property, Plant And Equipment | 73,886 | 94,046 | 109,481 | 117,960 | 123,061 |
Net Goodwill | |||||
Net Intangible Assets | |||||
Long Term Investments | |||||
Long Term Notes Receivable | |||||
Other Long Term Assets | |||||
Total Assets | 269,925 | 319,831 | 427,647 | 478,055 | 535,281 |
Accounts Payable | |||||
Accrued Expenses | |||||
Notes Payable / Short Term Debt | |||||
Current Portion of Long Term Debt / Capital Leases | |||||
Total Other Current Liabilities | |||||
Total Current Liabilities | 18,590 | 35,849 | 48,005 | 54,253 | 65,899 |
Long Term Debt | |||||
Capital Lease Obligations | |||||
Total Long Term Debt | |||||
Total Debt | |||||
Deferred Income Tax | |||||
Minority Interest | |||||
Total Other Liabilities | |||||
Total Liabilities | 60,851 | 74,409 | 122,205 | 134,552 | 102,178 |
Common Stock | |||||
Additional Paid In Capital | |||||
Retained Earnings (Accumulated Deficit) | |||||
Treasury Stock | |||||
ESOP Debt Guarantee | |||||
Unrealized Gain / Loss | |||||
Other Equity | |||||
Total Equity | 209,075 | 245,423 | 305,442 | 343,503 | 433,104 |
Total Liabilities & Shareholders' Equity | 269,925 | 319,831 | 427,647 | 478,055 | 535,281 |
Total Common Shares Outstanding | |||||
Total Preferred Shares Outstanding |